Oncology | Page 4 of 7 | www.PharmaNewsDaily.com

Home » Posts tagged with » Oncology (Page 4)

Lupin out-licenses MALT1 inhibitor program to AbbVie in $977m deal

December 25, 2018 No Comment

Indian pharma company Lupin has out-licensed its MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program to US biopharma company AbbVie in a deal potentially worth around $977 million. Lupin and AbbVie have forged a partnership in this regard which gives the US biopharma company the exclusive global rights to develop and commercialize the […]

Novartis proposes to acquire French CDMO CellforCure from LFB

December 23, 2018 No Comment

Novartis has proposed to acquire French contract development and manufacturing organizations (French CDMO) CellforCure from LFB for an undisclosed price. CellforCure is engaged in producing cell and gene therapies across Europe. The deal proposed by Novartis includes the cell and gene manufacturing facility in Les Ulis near Paris and the related adjacent land. If the […]

Incyte, Innovent announce collaboration for three cancer drugs in China

December 17, 2018 No Comment

US pharma company Incyte and Chinese biopharma company Innovent Biologics through their respective subsidiaries have entered into a deal worth up to $391.5 million for three investigational cancer drugs discovered and developed by the former. The three investigational cancer drugs – pemigatinib, a FGFR1/2/3 inhibitor, itacitinib, a JAK1 inhibitor and parsaclisib, a PI3Kδ inhibitor, are […]

Japanese pharma company Astellas acquires Potenza Therapeutics

December 16, 2018 No Comment

Astellas acquisition of Potenza : Japanese pharma company Astellas Pharma has exercised an option to acquire US-based Potenza Therapeutics in a deal worth up to $404.7 million. The acquisition is a result of a collaboration agreement signed by the two pharma companies in 2015 to develop a portfolio of novel immuno-oncology (IO) therapies. In the […]

Armas launches Azacitidine injection for myelodysplastic syndrome in US

November 19, 2018 No Comment

Armas Pharmaceuticals has launched its first injectable to the US market in the form of Azacitidine for Injection 100 MG, a Vidaza generic, used for the treatment of myelodysplastic syndrome. A type of cancer, myelodysplastic syndrome leads to low count of one or more blood cell types. In May 2004, Vidaza, a nucleoside metabolic inhibitor […]

IRX Therapeutics acquired by Brooklyn Immuno Therapeutics

November 19, 2018 No Comment

Pharma acquisition news : Brooklyn Immuno Therapeutics, a newly formed pharma company focused on developing for cytokine-based therapies for cancers, has acquired the assets of IRX Therapeutics for an undisclosed price. The New York-based Brooklyn ImmunoTherapeutics, which is a clinical-stage biopharma company, is developing IRX-2, a novel cytokine-based therapy for the treatment of patients with […]

Seattle Genetics’ Adcetris gets FDA approval for peripheral T-cell lymphoma

November 18, 2018 No Comment

Adcetris FDA approval : Seattle Genetics has secured new approval from the US Food and Drug Administration (FDA) for its monoclonal antibody Adcetris (brentuximab vedotin), which is in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) for the treatment of certain types of peripheral T-cell lymphoma (PTCL). Adcetris FDA approval for PTCL in combination with CHP […]

Pfizer lung cancer drug Lorbrena bags US FDA approval

November 3, 2018 No Comment

Lorbrena FDA approval : US pharma giant Pfizer has bagged approval from the US Food and Drug Administration (FDA) for Lorbrena (lorlatinib) for anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC). Lorbrena FDA Approval The FDA approval of Lorbrena is for the ALK-positive NSCLC patient population whose condition has progressed on treatment […]

Novartis to acquire US biopharma company Endocyte for $2.1bn

October 21, 2018 No Comment

Swiss pharma giant Novartis has signed a deal valued at about $2.1 billion to acquire US biopharma company Endocyte in a move to expand its expertise in radiopharmaceuticals for the treatment of cancer. According to the merger terms, the Swiss pharma giant will buy all the shares of Endocyte at $24 per share. The US […]

Five Prime, Zai Lab initiate phase 3 trial of bemarituzumab chemo combo

October 1, 2018 No Comment

Five Prime Therapeutics and Zai Lab have dosed the first patient in a phase 3 study of bemarituzumab (FPA144) in combination with chemotherapy in patients having advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The late-stage trial named as FIGHT features advanced gastric cancer or gastroesophageal junction cancer patients who were not subjected to […]